

1

## Supplementary Material

### 2 **Dual-sensitive chitosan derivative micelles for site-specific drug** 3 **release in treatment of chicken coccidiosis**

4

5 Xin Zhang <sup>a, 1</sup>, Gujun Xu <sup>a, 1</sup>, Khalid Gadora <sup>a</sup>, Hao Cheng <sup>a</sup>, Jin Peng <sup>a</sup>, Yong Ma <sup>b</sup>,  
6 Yang Guo <sup>b</sup>, Cheng Chi <sup>a</sup>, Jianping Zhou <sup>a, \*</sup>, Yang Ding <sup>a, \*</sup>

7

8 <sup>a</sup> State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China  
9 Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.

10 <sup>b</sup> Institute of Traumatology & Orthopedics, Nanjing University of Chinese Medicine,  
11 Nanjing 210023, China.


12

13

14

15

16



17

18 **Fig. S1.** The fluorescence intensity ratio of I<sub>338</sub>/I<sub>333</sub> of CS-CPBA/pyrene solution  
19 excitation spectrum.

20

21 **Table S1** Bloody feces counted during 5-7 days after challenge with *Eimeria tenella*  
 22 (Results expressed as pooled bloody feces from 10 chicks in each group).

Groups	Days after challenge			Total bloody feces
	5	6	7	
Uninfected control	0	0	0	0
Infected control	11	6	6	23
DIC/CS-CPBA	4	2	6	12
DIC suspensions	6	8	5	19

23

24 **Table S2** Intestinal lesions examined at eight days after challenge with *Eimeria*  
 25 *tenella*. Data presented as mean  $\pm$  S.D. (n= 10)

Groups	Lesion scores
Uninfected control	0
Infected control	0.62 $\pm$ 0.92
DIC/CS-CPBA	0.12 $\pm$ 0.35
DIC suspensions	0.25 $\pm$ 0.71

26